Rapid Activity of Platelet Inhibitor Drugs Study 2
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The aim of the RAPID study is to evaluate the superiority rapid onset of action of Ticagrelor
360 mg LD versus Prasugrel 60 mg LD, in 50 patients with STEMI (ST segment elevation
myocardial infarction) undergoing PPCI with bivalirudin monotherapy. Secondary study aim is
to found out clinical predictors of high residual platelet reactivity in the first hour after
a novel oral antiplatelet agent LD.